Dr. James Mark Cleary, MD, PhD

Dr. Cleary practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Cleary's NPI, 1922062397, was assigned on April 13, 2006. Dr. Cleary graduated from Albert Einstein College of Medicine of Yeshiva University in 2003. Dr. Cleary holds Massachusetts license 226742.

Dr. Cleary's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Cleary's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Cleary is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Cleary to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cleary practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Cleary's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Cleary is licensed in Massachusetts.

CMS data shows 369 Medicare services from Dr. Cleary across 4 procedure codes in 2024, all of them office visits, for 88 Medicare patients. Medicare paid $37,499 for them.

CMS counts 88 Medicare patients who saw Dr. Cleary in 2024. The largest group is 65 to 74, with 49 patients. 67% of them have high blood pressure, and 67% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cleary's median patient age at 70, with 47% women.

In 2024, Dr. Cleary wrote 242 Medicare Part D claims for 44 patients. 88% of them were for generic drugs. CMS names the drug for 138 of them, across 9 drugs with 11 or more claims each, at $1,476 in total drug cost. In 2023, CMS named 43 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Cleary for performance year 2024, reported as part of a group. Dr. Cleary accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cleary as offering telehealth.

Dmand AI links 106 papers to Dr. Cleary, published from 2012 to 2025. 2024 was the busiest year, with 15. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms and Protein Kinase Inhibitors. Dr. Cleary has published most often in Clin Cancer Res. Dr. Cleary's most frequent co-authors are Geoffrey Ira Shapiro, MD, PhD, Andrew J. Aguirre, MD, PhD and Harshabad Singh, MD.

Dmand AI links Dr. Cleary to 10 clinical trials, 5 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Anus Neoplasms and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 64 general payments to Dr. Cleary from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Genentech, Inc. paid the most, $14,802. It also lists 1 research payment totaling $2,006 in 2023.

Dr. Cleary graduated from Albert Einstein College of Medicine of Yeshiva University in 2003.